In brief

BMJ 1997; 315 doi: (Published 27 September 1997) Cite this as: BMJ 1997;315:763

Malaria guidelines emphasise risks of preventive treatment: New guidance from the Malaria Reference Laboratory says that the risk of malaria must be balanced against the risk of adverse reactions to antimalarial drugs. Mefloquine treatment carries the risk of neuropsychiatric reactions, so it should be used only when the risk of acquiring malaria that is highly resistant to chloroquine is high (Communicable …

View Full Text

Log in

Log in through your institution


* For online subscription